temozolomide has been researched along with stattic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes, U; Dkhissi, F; Dusanter-Fourt, I; Karayan-Tapon, L; Le Corf, A; Martin-Lannerée, S; Tourani, JM; Turhan, AG; Villalva, C; Wager, M | 1 |
| Chen, Y; Guan, Q; Guo, Y; Ji, G; Jin, Y; Li, C; Liu, P; Ma, Y; Mu, Y; Sun, D; Sun, H; Wu, N; Xu, Y; Zhang, Y; Zhao, M; Zhou, C | 1 |
2 other study(ies) available for temozolomide and stattic
| Article | Year |
|---|---|
STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Cyclic S-Oxides; Dacarbazine; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Neural Stem Cells; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; STAT3 Transcription Factor; Temozolomide; Tumor Cells, Cultured | 2011 |
RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Oncogenes; Ribosomal Proteins; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays | 2023 |